Bristol Meyers Squibb vs Takeda

1033 WordsMar 27, 20115 Pages
Bristol Meyers Squibb vs Takeda Vidhya Nagabhushans Antitrust laws were essentially created to stop businesses that got too large from blocking competition and abusing their power. Mergers and monopolies can limit the choices offered to consumers because smaller businesses are not usually able to compete. Although free and open competition ensures lower prices and new and better products, it has the potential to significantly limit market diversity. Bristol-Myers Squibb, our BioPharma strategy uniquely combines the reach and resources of a major pharma company with the entrepreneurial spirit and agility of a successful biotech company. With this strategy, we focus on our customers’ needs, giving maximum priority to…show more content…
The possible ethical dilemmas present in this example are the Federal Trade Commission (FTC) conducting the investigation against a pharmaceutical company for not allowing generic drugs to the market because most pharmaceutical company would allow generic drugs into the market because they understand that not everybody is able to afford name brand drugs and people need the medications in order to cure the disease they have been diagnosed with, and to help them deal with their day to day lives. I think that the FTC should try to understand and maybe see where the pharmaceutical company is coming from and see if there is a way for the drug company and the FTC to come up with a solution in order to help people and not have the drug company loose any money or profits with people buying generic drugs rather than purchasing name brand drugs the company is selling to the general market. Takeda is a research-based global pharmaceutical company. As the largest pharmaceutical company in Japan and one of the global leaders of the industry. Setting our management philosophy, “Takeda-ism” as the basis of Business, Takeda is committed to striving towards better health for patients worldwide through leading innovation in medicine. Takeda is enhancing its R&D pipeline by concentrating its management resources. Takeda's in-house ethical drugs are marketed in around 90 countries worldwide and are recognized as the brand in major countries worldwide. We strive towards better health
Open Document